Golotimod (SCV-07) is compound that has been investigated as a medicine for the treatment of tuberculosis, and various other viral and bacterial infections. Golotimod acts broadly on the Toll-like receptor (TLR) pathway. It stimulates the T-helper 1 (Th1) type immune response and blocks signal transducers and activator of transcription 3 (STAT3) mediated signaling. Treatment of tuberculosis with golotimod improves clearance of mycobacteria, cavity healing, and immune parameters and also reduced symptoms (such as fever, weakness, sweating, dry cough, productive cough, dyspnea, chest pain, tachycardia) without adverse effects. Phase II clinical trials have been completed to assess its safety and tolerability.

Dymanthine (Thelmesan) is an Anthelmintic, it is prepared as the hydrochloride and has some activity against hookworm infection, ascariasis, trichuriasis and hymenolepiasis. The drug appears to be safe, well tolerated and to cause few side effects (nausea, vomiting, headache, diarrhea, giddiness).

Clonitrate (chloroglyceryl dinitrate) is a derivative of nitroglycerin. The compound is identical with glycerol trinitrate with the exception of the replacement of the nitrate radical on the first carbon atom by an atom of chlorine. Clonitrate is equipotent with glycerine trinitrate in increasing coronary flow in Langendorff rabbit heart and appears to evoke a lesser degree of depressor response. In the 1960s, clonitrate was used in the clinics a vasodilator for the treatment of angina pectoris.